EP0223842A4 - Monoklonaler antikörper gegen zerfallakzelerationsfaktor, dessen herstellung und verwendung. - Google Patents

Monoklonaler antikörper gegen zerfallakzelerationsfaktor, dessen herstellung und verwendung.

Info

Publication number
EP0223842A4
EP0223842A4 EP19860903931 EP86903931A EP0223842A4 EP 0223842 A4 EP0223842 A4 EP 0223842A4 EP 19860903931 EP19860903931 EP 19860903931 EP 86903931 A EP86903931 A EP 86903931A EP 0223842 A4 EP0223842 A4 EP 0223842A4
Authority
EP
European Patent Office
Prior art keywords
daf
making
monoclonal antibody
accelerating factor
decay accelerating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19860903931
Other languages
English (en)
French (fr)
Other versions
EP0223842A1 (de
Inventor
Taroh Kinoshita
M Edward Medof
Victor Nussenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of EP0223842A1 publication Critical patent/EP0223842A1/de
Publication of EP0223842A4 publication Critical patent/EP0223842A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP19860903931 1985-05-24 1986-05-23 Monoklonaler antikörper gegen zerfallakzelerationsfaktor, dessen herstellung und verwendung. Withdrawn EP0223842A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73817185A 1985-05-24 1985-05-24
US738171 1985-05-24

Publications (2)

Publication Number Publication Date
EP0223842A1 EP0223842A1 (de) 1987-06-03
EP0223842A4 true EP0223842A4 (de) 1987-08-24

Family

ID=24966867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860903931 Withdrawn EP0223842A4 (de) 1985-05-24 1986-05-23 Monoklonaler antikörper gegen zerfallakzelerationsfaktor, dessen herstellung und verwendung.

Country Status (3)

Country Link
EP (1) EP0223842A4 (de)
JP (1) JPS63500797A (de)
WO (1) WO1986007062A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
JP3562834B2 (ja) * 1994-06-01 2004-09-08 孝夫 辻 便中ｄａｆ分子の検査方法
SI1157041T1 (sl) * 1999-03-01 2005-12-31 Genentech Inc Protitelesa za terapijo in diagnozo raka
DE60020529T2 (de) 1999-03-01 2006-04-27 Genentech Inc., San Francisco Antikörper zur krebsbehandlung und -diagnose
FR3080182B1 (fr) 2018-04-12 2020-03-20 Sartorius Stedim Fmt Sas Procede et dispositif de controle d’integrite d’une poche pour fluide biopharmaceutique
FR3080181B1 (fr) 2018-04-12 2020-03-20 Sartorius Stedim Fmt Sas Procede et dispositif de controle d’integrite d’une poche pour fluide biopharmaceutique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *
See also references of WO8607062A1 *

Also Published As

Publication number Publication date
JPS63500797A (ja) 1988-03-24
WO1986007062A1 (en) 1986-12-04
EP0223842A1 (de) 1987-06-03

Similar Documents

Publication Publication Date Title
HUT38391A (en) Process for preparing new monoclonal antibodies against glycoconjugates and for the utilization thereof
GB8608068D0 (en) Monoclonal antibodies
GB8426467D0 (en) Monoclonal antibodies
GB8422650D0 (en) Monoclonal antibodies
EP0223842A4 (de) Monoklonaler antikörper gegen zerfallakzelerationsfaktor, dessen herstellung und verwendung.
GB8426463D0 (en) Monoclonal antibodies
GB8422653D0 (en) Monoclonal antibodies
EP0203967A4 (de) Oncofetal spezifische monoklonale antikörper, deren herstellung und verwendung.
GB8530829D0 (en) Monoclonal antibodies
PT79896A (en) Monoclonal antibody
EP0124548A4 (de) Babesiosis-antigen und dessen herstellungsverfahren.
GB8517895D0 (en) Monoclonal antibodies
GB8426461D0 (en) Monoclonal antibodies
AU5965086A (en) Monoclonal antibody to decay accelerating factor (DAF), a method for making it, and use
GB8422651D0 (en) Monoclonal antibodies
GB8422649D0 (en) Monoclonal antibodies
GB8426468D0 (en) Monoclonal antibodies
GB8426464D0 (en) Monoclonal antibodies
GB8426470D0 (en) Monoclonal antibodies
GB8426459D0 (en) Monoclonal antibodies
GB8426465D0 (en) Monoclonal antibodies
GB8419456D0 (en) Monoclonal antibodies
GB8416845D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
GB2175918B (en) Monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870604

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KINOSHITA, TAROH

Inventor name: NUSSENZWEIG, VICTOR

Inventor name: MEDOF, M., EDWARD

A4 Supplementary search report drawn up and despatched

Effective date: 19870824

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MEDOF, M., EDWARD

Inventor name: KINOSHITA, TAROH OSAKA UNIVERSIT MEDICAL SCHOOL

Inventor name: NUSSENZWEIG, VICTOR

17Q First examination report despatched

Effective date: 19890502

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900113

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NUSSENZWEIG, VICTOR

Inventor name: MEDOF, M., EDWARD

Inventor name: KINOSHITA, TAROHOSAKA UNIVERSITY MEDICAL SCHOOL